A company combining computation and drug development
Iambic Therapeutics develops medicines using AI alongside experimental discovery. Its current founder biographies date the company’s founding to October 2019. Its research tools are part of a therapeutic-development organization, rather than an independent regulatory evaluator. [1][2]
Connecting discovery data to clinical properties
Iambic announced Enchant in October 2024 and released a technical whitepaper. The multimodal transformer combines abundant preclinical data with smaller amounts of human data to predict properties such as pharmacokinetics, how a drug behaves in the body. [2]
Predictions guide experiments
The company presented retrospective demonstrations of predictive performance. Those results can inform candidate selection, but do not themselves show that future trials will succeed, that development time will fall by a particular amount or that a resulting drug is approved. [3]
Sources
- About | Iambic Therapeutics
Iambic Therapeutics · retrieved Oct 23, 2026
- Iambic Therapeutics Announces “Enchant,” an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery
Iambic Therapeutics · Oct 29, 2024
- Enchant whitepaper: Breaking the data wall between lab and clinic
Iambic Therapeutics · Oct 29, 2024